Qingdao Haier Biomedical Co.,Ltd financials at a glance

+ Portfolio

The revenue of Qingdao Haier Biomedical Co.,Ltd is reported as 2.2809 billion Yuan Renminbi in the fiscal year 2023. The earnings were 1.04 Yuan Renminbi per share in 2023, which was 38.1 lower than 2022. And about 0.07208 billion Yuan Renminbi are reported as free cash flow in the financials of Qingdao Haier Biomedical Co.,Ltd 2023. Dividends of 0 Yuan Renminbi per share were paid to shareholders of Qingdao Haier Biomedical Co.,Ltd stock SHSE:688139 in fiscal 2023.

¥2.28B

Revenue

¥1.04

Earnings Per Share

50.56%

Gross Margin %

¥0.00M

Free Cash Flow

Revenue

2,280.90

Earnings Per Share

1.04

Gross Margin %

50.56

Free Cash Flow

0.00

Financials

Year	Year	TTM	2023	2022	2021	2020
Rev.	Revenue	N/A	¥2.28B	¥2.86B	¥2.13B	¥1.40B
GM %	Gross Margin %	50.59%	50.56%	47.97%	50.08%	50.40%
OM	Operating Margin	17.07%	13.72%	19.72%	20.79%	21.61%
EPS	Earnings Per Share	¥1.56	¥1.04	¥1.68	¥1.32	¥0.99
Div.	Dividends	N/A	¥0.00	¥0.00	¥0.00	¥0.00
PR %	Payout Ratio %	0	0	0	0	0
Sha.	Shares	N/AM	315.68M	316.49M	317.07M	317.07M
OCF	Operating Cash Flow	N/A	¥249.26M	¥632.43M	¥591.80M	¥696.62M
FCF	Free Cash Flow	N/A	¥72.08M	¥338.19M	¥387.11M	¥607.63M
FCFS	Free Cash Flow Per Share	¥1.21	¥0.23	¥1.06	¥1.22	¥1.91

Qingdao Haier Biomedical Co.,Ltd financials at a glance

Financials

Discover